Literature DB >> 29909135

Evaluation of carbopol as an adjuvant on the effectiveness of progressive atrophic rhinitis vaccine.

Jiansong Zhang1, Meifen Wang1, Nini Zhou1, Yijuan Shen1, Yufeng Li2.   

Abstract

The Gram-negative pathogen toxigenic P. multocida causes progressive atrophic rhinitis (PAR) in swine throughout the world. Although some vaccines are being developed against PAR, their efficacy has not been evaluated using carbopol. In our study, a mixture of killed B. bronchiseptica and P. multocida bacteria, combined with recombinant proteins containing the C- and N-termini of PMT, was emulsified using two different adjuvants (ISA-15A and carbopol 971). The efficacy of these two vaccines was evaluated in a mouse model. Balb/C mice were immunized twice at a 14-day interval. Two weeks after the secondary immunization, blood samples were collected and the mice were challenged with toxigenic P. multocida. Thirty-five days later, the mice were euthanized, blood and tissue samples were collected. Compared with mice inoculated with vaccine emulsified with ISA-15A, higher titers of SN (1:64) and significantly increased levels of TNF-α, IL-6 and IL-17A were observed in mice inoculated with vaccine emulsified with the carbopol 971P. Especially, mice immunized with vaccine emulsified with the carbopol 971P had no detectable pathological changes in snouts or organs after challenge. The results demonstrated that carbopol adjuvanted vaccine provides good protection against PAR and P. multocida infection which can induce robust humoral and cell-mediated responses. We conclude that the carbopol adjuvanted vaccine is a good candidate for PAR prevention.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atrophy of turbinate; Carbopol; Cytokines; PAR; Toxigenic P. multocida

Mesh:

Substances:

Year:  2018        PMID: 29909135     DOI: 10.1016/j.vaccine.2018.06.023

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Molecular epidemiology of Porcine Parvovirus Type 1 (PPV1) and the reactivity of vaccine-induced antisera against historical and current PPV1 strains.

Authors:  Nick Vereecke; Lise Kirstine Kvisgaard; Guy Baele; Carine Boone; Marius Kunze; Lars Erik Larsen; Sebastiaan Theuns; Hans Nauwynck
Journal:  Virus Evol       Date:  2022-06-16

2.  Immunogenicity of a new, inactivated canine adenovirus type 2 vaccine for dogs.

Authors:  Dong-Kun Yang; Ha-Hyun Kim; Jae Young Yoo; Miryeon Ji; Bok Hee Han; Subin Oh; Bang-Hun Hyun
Journal:  Clin Exp Vaccine Res       Date:  2020-01-31

3.  Field evaluation of the safety and compatibility of a combined vaccine against porcine parvovirus 1 and porcine reproductive and respiratory syndrome virus in breeding animals.

Authors:  Beatriz Garcia-Morante; Marta Noguera; Christian Kraft; Philip Bridger
Journal:  Porcine Health Manag       Date:  2019-12-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.